Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The rising pandemic of obesity an type 2 diabetes, both manifestations of insulin resistance, has heralded a rise in associated liver injury in the form of non-alcoholic fatty liver desease (NAFLD). It is estimated that 20-30% of the population in developed countries have NAFLD, NAFDL should be suspected in those with simple clinical signs and biochemistry consistent with insulin resistance. The importance of NAFDL is two-fold. Firstly, a small number of individuals with NAFDL, itself a relatively benign condition, will progress to more severe stages of liver disease - namely, non-alcoholic steatohepatitis (NASH), cirrhosis and hepatocellular carcinoma. Secondly, the presence of NAFDL is associated with treatable features of insulin resistance and an elevated risk for type 2 diabetes. Apart from histology, there is currently no effective method t o distinguish between NASH and simple steatosis. Identification of a non-invasive marker to achieve this is much sought after. Pilot studies of lifestyle advice, insulin sensitisers and other medications have shown evidence of improvement in liver histology and serum ALT. However, the cost shown benefit ratio of any new therapies, and any potential harms, must be examined carefully before clinically advocated. Copyright © 2007 John Wiley & Sons.

Original publication




Journal article


Practical Diabetes International

Publication Date





310 - 316